{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:36:34Z","timestamp":1770881794851,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To describe characteristics and outcomes of patients with retinopathy of prematurity who failed intravitreal antivascular endothelial growth factor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective case series of 211 eyes (112 patients) treated with antivascular endothelial growth factor as initial therapy for retinopathy of prematurity at a single academic institution between 2011 and 2019 and an additional 6 eyes (3 patients) referred to us for management of failed antivascular endothelial growth factor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among the 211 eyes receiving initial treatment at our institution, 17 eyes (11%) failed. Of the 23 total eyes managed by us for failure, 3 eyes (13%) failed after 50-week postmenstrual age. Failure manifested as recurrent plus in 14 eyes (58%), recurrent Stage 3 in 13 eyes (54%) and retinal detachment in 5 eyes (21%). Treatment failures were managed with laser (13 eyes), repeat injection (4 eyes), vitrectomy (2 eyes), or a combination of modalities (4 eyes). Follow-up of \u22656 months was available for 18 of the 23 eyes. The retina was fully attached in 17 eyes, and fixation behavior was present in 10 eyes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The most common manifestations of treatment failure were recurrent plus and Stage 3. The failure rate at our institution was 11.0%. A significant proportion of failures occurred after 50-week postmenstrual age. Most failed eyes had favorable anatomical outcomes and over half demonstrated fixation behavior.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003249","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T15:35:57Z","timestamp":1625067357000},"page":"2269-2277","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["CLINICAL FEATURES AND OUTCOMES OF INFANTS WITH RETINOPATHY OF PREMATURITY WHO FAIL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY"],"prefix":"10.1097","volume":"41","author":[{"given":"Lucy T.","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy K.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prethy","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George B.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"149.e1","DOI":"10.1016\/j.jaapos.2020.03.003","article-title":"Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity","volume":"24","author":"Rodriguez","year":"2020","journal-title":"J AAPOS"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1111\/aos.12339","article-title":"Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity","volume":"92","author":"Moran","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"R9-20250607","first-page":"355","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up","volume":"109","author":"O'Keeffe","year":"2016","journal-title":"Ir Med J"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.12659\/MSM.897095","article-title":"Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis","volume":"22","author":"Nicoara","year":"2016","journal-title":"Med Sci Monit"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","article-title":"Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"2","author":"Roohipoor","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11845-017-1684-y","article-title":"Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity","volume":"187","author":"Sahin","year":"2018","journal-title":"Ir J Med Sci"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J AAPOS"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","article-title":"Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab","volume":"38","author":"Yonekawa","year":"2018","journal-title":"Retina"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","article-title":"Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"Patel","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/ICB.0b013e318285238e","article-title":"Delayed recurrent neovascularization and persistent avascular retina following intravitreal bevacizumab for retinopathy of prematurity","volume":"7","author":"Mehta","year":"2013","journal-title":"Retin Cases Brief Rep"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaapos.2018.10.013","article-title":"Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP","volume":"23","author":"Anand","year":"2019","journal-title":"J AAPOS"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/aos.13004","article-title":"Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison","volume":"96","author":"Han","year":"2018","journal-title":"Acta Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:05:10Z","timestamp":1749319510000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003249","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}